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 Background:  The global burden of sepsis is estimated as 15 to 19 million cases annually 
with a mortality rate approaching 60% in low income countries.   
Methods:   In this retrospective before-after clinical study, we compared the outcome and 
clinical course of consecutive septic patients treated with intravenous vitamin C, 
hydrocortisone and thiamine during a 7-month period (treatment group) compared to a 
control group treated in our ICU during the preceding 7 months.  The primary outcome was 
hospital survival.  A propensity score was generated to adjust the primary outcome.   
 Findings:  There were 47 patients in both treatment and control groups with no significant 
differences in baseline characteristics between the two groups.  The hospital mortality was 
8.5% (4 of 47) in the treatment group compared to 40.4% (19 of 47) in the control group (p 
< 0.001). The propensity adjusted odds of mortality in the patients treated with the vitamin 
C protocol was 0.13 (95% CI 0.04-0.48, p=002). The SOFA score decreased in all patients in 
the treatment group with none developing progressive organ failure.  Vasopressors were 
weaned off all patients in the treatment group, a mean of 18.3 ± 9.8 hours after starting 
treatment with vitamin C protocol. The mean duration of vasopressor use was 54.9 ± 28.4 
hours in the control group (p<0.001).  
  Conclusion: Our results suggest that the early use of intravenous vitamin C, together with 
corticosteroids and thiamine may prove to be effective in preventing  progressive organ 
dysfunction including acute kidney injury and reducing the mortality of patients with 
severe sepsis and septic shock. Additional studies are required to confirm these 
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    The global burden of sepsis is substantial with an estimated 15 to 19 million cases per 
year; the vast majority of these cases occur in low income countries.1 With more timely 
diagnosis and improvement in supportive care the 28-day mortality from sepsis in high 
income countries has declined to about 25%; however, the mortality rate from septic shock 
remains as high as 50%. 2-5  Moreover, the mortality from sepsis and septic shock in low 
income countries is approximately 60%.6-8 In addition to short term mortality, septic 
patients suffer from numerous short- and long-term complications with a reduced quality 
of life and an increased risk of death up to five years following the acute event.9-11 Over the 
last 3 decades, over 100 phase II and phase III clinical trials have been performed testing 
various novel pharmacologic agents and therapeutic interventions in an attempt to 
improve the outcome of patients with severe sepsis and septic shock; all of these efforts 
ultimately failed to produce a novel pharmacologic agent to directly target the 
pathophysiologic effects of severe sepsis. 12 New therapeutic approaches to sepsis are 
desperately required. To impact the global burden of sepsis these interventions should be 
effective, cheap, safe and readily available.  
 
    We were recently confronted with three patients with fulminant sepsis who were 
almost certainly destined to die from overwhelming septic shock.  Based on experimental 
and emerging clinical data, we decided to administer intravenous vitamin C to these 
patients as a life-saving measure.13-17 “Moderate-dose” hydrocortisone was added for its 
theoretical synergistic benefit.  All three of these patients made a dramatic recovery and 
were discharged from the ICU within days with no residual organ dysfunction. Based on 
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intervention, the combination of intravenous vitamin C and corticosteroid became 
routinely used as adjunctive therapy for the treatment of severe sepsis and septic shock in 
our ICU. Patents with sepsis predictably have very low serum vitamin C levels, which can 
only be corrected with intravenous vitamin C in a dose of more than 3gm per day. 16;18;19 
Based on published clinical data, vitamin C pharmacokinetic modeling as well as the 
package insert, we decided to administer 6gm vitamin C per day divided in 4 equal      
doses. 16;18-23  This dosage is devoid of any reported complications or side effects. Dosages 
as high as 100-150gm have been safely administered to patients with burns and 
malignancy.17;24;25 Hydrocortisone was dosed according to the consensus guidelines of the 
American College of Critical Care Medicine.26 Intravenous thiamine (vitamin B1) was added 


















This study was an Electronic Health Record (EHR) based retrospective before-after 
clinical study.28  The study was approved by our Institutional Review Board (#16-08-WC-
0179) and the Sentara Health System Office of Research (16-08-SRC-88).  This study was 
conducted at Sentara Norfolk General Hospital, a tertiary care referral hospital affiliated 
with Eastern Virginia Medical School (EVMS) and the only tertiary care facility in the 
Hampton Roads area serving a population of approximately 1.8 million people.  Between 
January 2016 and July 2016, consecutive patients admitted to the EVMS Critical Care 
Medicine service in the General ICU at Sentara Norfolk General Hospital with a primary 
diagnosis of severe sepsis or septic shock and a procalcitonin (PCT) ≥ 2ng/ml were treated 
with intravenous hydrocortisone, vitamin C and thiamine (vitamin C protocol) within 24 
hours of ICU admission (treatment group). PCT is routinely measured in our hospital as a 
screening tool for sepsis and to follow the evolution of the disease. 29-32 PCT is measured in 
our laboratory using the VIDAS BRAHMS PCT assay, a one-step immunoassay sandwich 
method with final fluorescent detection (BioMerieux, Inc. Marcy l’Etoile, France); the lower 
limit of PCT detection was 0.05ng/ml. Septic patients with a PCT < 2ng/ml within the first 
24 hours of ICU admission were not treated with the vitamin C protocol.  We used a 
threshold PCT of 2ng/ml to increase the certainty that the patients had severe sepsis and 
were at risk of developing sepsis-related organ dysfunction.32-34   Patients less than < 18 
years of age, pregnant patients and patients with limitations of care were not treated with 
the vitamin C protocol.  The control group consisted of a similar number of consecutive 
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inclusion and exclusion criteria as the treatment group. During the control period, patients 
with sepsis did not receive intravenous vitamin C or thiamine. The diagnosis of  severe 
sepsis and septic shock were based on the 1992 American College of Chest 
Physicians/Society of Critical Care Medicine Consensus Conference definitions.35   
 
  We queried our EHR (EPIC, Verona, Wisconsin) to identify patients that met the 
inclusion criteria for the treatment and control groups. The patients’ clinical and 
demographic data including age, sex, admitting diagnosis, co-morbidities, requirement for 
mechanical ventilation, use of vasopressors (and hourly dosages), daily urine output (for 
first 4 days), fluid balance after 24 and 72 hours, length of ICU stay (LOS) and laboratory 
data were abstracted from the EHR.   Patients were considered immunocompromised if 
they were taking more than 10 mg of prednisone-equivalent per day for at least 2 weeks, 
were receiving cytotoxic therapy or were diagnosed with the acquired immunodeficiency 
syndrome. The hourly dosage of vasopressors was recorded as the norepinephrine 
equivalent dosage. 36;37 The serum creatinine, white cell count (WBC), platelet count, total 
bilirubin, PCT and lactate levels were recorded daily for the first 4 days. Acute kidney 
injury (AKI) was defined using the KDIGO criteria; namely, an increase of the serum 
creatinine > 0.3 mg/dl or a level > 1.5 times the baseline value.38 If the baseline serum 
creatinine was not known a value > 1.5 mg/dl was regarded as diagnostic of AKI. The 
patient’s admission APACHE II and APACHE IV scores including the APACHE IV predicted 
hospital mortality were recorded. The APACHE II score (incrementing score of 0-71) and 
APACHE IV score (incrementing score 0-286) are standardized measures of disease 
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Failure Assessment) score was calculated daily for 4 days. The SOFA score was designed to 
sequentially assess the severity of organ dysfunction in patients who were critically ill from 
sepsis (incrementing score 0-24). 41  The SOFA scores were calculated 24 hours after 
admission to the ICU and daily thereafter.   
 
ICU management protocol42 
 The overall management of patients with sepsis during the control and treatment 
periods was similar except for the administration of the combination of vitamin C, 
hydrocortisone and thiamine during the treatment period.  There were no known 
significant changes to our ICU protocols, referral patterns, or patient population during the 
study period.  During the control period patients received hydrocortisone (50 mg q 6 
hourly)  per current guidelines and at the discretion of the attending physician.26;42;43 As 
per standard operating procedure in our ICU, all patients with sepsis and septic shock are 
started empirically on broad spectrum antibiotics which are then deescalated according to 
microbiological data and clinical progress, 44 are managed by a conservative physiologic 
based fluid and vasopressor strategy, 45;46 and are ventilated with a lung protective  
strategy 46;47 avoiding hyperoxia48 and with the limited use of sedative agents 
(dexmedetomidine preferred agent).49  Norepinephrine is the vasopressor of first choice 
and titrated to a dose of 20 ug/min targeting a mean arterial pressure > 65 mmHg. In 
patients failing to achieve this target, fixed dose vasopressin was then added at 0.04 
units/min followed by phenylephrine or epinephrine.42;45 Patients receive enteral nutrition 
with a whey-based formula (Vital 1.2, Abbott, Colombia, OH) using an intermittent bolus 
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achieved, 50;51 they receive deep venous thrombosis prophylaxis with both enoxaparin (or 
heparin in patients with a calculated creatinine clearance < 30 ml/min)  and sequential 
compression and we allow permissive hyperglycemia.52 Routine stress ulcer prophylaxis is 
not administered. 53 During the treatment period consecutive patients with a primary 
admitting diagnosis of severe sepsis or septic shock and a PCT > 2 ng/ml were treated with 
intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge), hydrocortisone 
(50 mg q 6 hourly for 7 days or until ICU discharge followed by a taper over 3 days) as well 
as intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge).   The 
vitamin C was administered as an infusion over 30 to 60 minutes and mixed in a 100ml 
solution of either dextrose 5% in water (D5W) or normal saline. Intravenous thiamine was 
given as a piggyback in 50 ml of either D5W or normal saline and was administered as a 30-
minute infusion. We attempted to obtain a vitamin C level prior to the first dose of vitamin 
C.  The vitamin C assay was performed at LabCorp (Burlington, NC) by high-pressure liquid 
chromatography (HPLC) with electrochemical detection.  The specimens were collected in 
a serum separation gel tube, protected from light and transported on ice.  The specimens 
were frozen prior transport to the local reference laboratory (LabCorp, Norfolk VA). 
  
Data analysis: 
The first three “pivotal” cases treated with the vitamin cocktail were excluded from 
analysis. The patients’ deidentified clinical and laboratory data were recorded in an 
electronic spreadsheet.  The primary outcome was hospital survival.  Secondary outcomes 
included duration of vasopressor therapy, 54 requirement for renal replacement therapy 
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the first 72 hours. 30;55-58  The procalcitonin clearance (PCT-c) was calculated using the 
following formula: initial PCT minus PCT at 72 hours, divided by the initial PCT multiplied 
by 100. 57;59 Summary statistics were used to describe the clinical data and presented as 
mean ± SD, median and interquartile range (IQR) or percentages as appropriate.  Chi 
squared analysis with Fisher’s exact test (when appropriate) and Student’s t test (Mann 
Whiney U test for non-normal distributions) were used to compare data between the 
treatment and control groups with statistical significance declared for probability values of 
0.05 or less.   Logistic discriminant analysis was performed on the entire data set to 
determine the independent predictors of survival. Statistical analysis was performed using 
NCSS 11 (Kaysville, Utah) and IBM SPSS Statistics Version 24 (IBM, Armonk, NY). 
 
 To adjust for potential baseline differences between the treatment and control 
groups, SPSS statistics was used to generate propensity scores for the patients’ likelihood 
to receive the vitamin C protocol.  Factors included in propensity score generation included 
age, weight, gender, APACHE 4 score, need for mechanical ventilation at presentation, use 
of vasopressor agents at presentation, WBC count at presentation, serum lactate level at 
presentation, procalcitonin level at presentation and serum creatinine at presentation (see 
e-Table 1). Binary logistic regression with propensity score adjustment was then 
performed to assess odds ratio for mortality by treatment group.60  This analysis was then 
repeated with both age and propensity score adjustments to assess the odds ratio for 
mortality (see e-Table 2). The propensity score distribution for the treatment and control 
group is presented in e-Figure 1 while the APACHE IV distribution between the treatment 


















There were 47 patients in each group. The baseline characteristics of the two groups 
are presented in Table 1; with no significant differences in baseline characteristics between 
the two groups. Most patients had multiple comorbidities with only 2 patients in the 
treatment group and one in the control group being previously “healthy”.  The distribution 
of infections was similar between the two groups with the lung being the most common 
site of infection.  Blood cultures were positive in 13 patients (28%) in each group.  
Escherichia coli (n=6) and gram +ve organisms (n=3) were the commonest blood isolates in 
the treatment group while gram +ve organisms (n=6) and E. Coli (n=4) were the 
commonest isolates in the control group. Correctly timed baseline vitamin C levels were 
available in 22 patients in the treatment group; the mean level was 14.1 ± 11.8 umol/l 
(normal 40-60 umol/l) with no patient having a normal level. Twenty-two (47%) patients 
in each group were treated with vasopressor agents and met the criteria for septic shock.  
The primary and secondary outcomes are provided in Table 2. The hospital mortality was 
8.5% (4 of 47 patients) in the treatment group compared to 40.4% (19 of 47 patients) in 
the control group (p < 0.001). The predicted and actual mortality for the treatment and 
control groups is illustrated in Figure 1. Logistic discriminant analysis identified three 
independent predictors of mortality, namely, treatment with the vitamin C protocol (F-
value 17.33, p< 0.001), the APACHE IV Score (F-value 13.29, p< 0.001) and need for 
mechanical ventilation (F-value 3.75, p=0.05). The propensity adjusted odds of mortality in 
patients treated with the vitamin C protocol was 0.13 (95% CI 0.04-0.48, p=002). None of 
the patients in the treatment group died from complications related to sepsis. All these 
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from complications of their underlying disease (advanced dementia, severe heart failure, 
advanced sarcoidosis and severe COPD).  
 
Twenty-eight (59.6%) patients in the control group were treated with 
hydrocortisone.  Thirty-one patients (66%) in the treatment group met the criteria for AKI 
compared 30 (64%) in the control group (NS). Three patients (10%) with AKI in the 
treatment group required RRT compared to 11 (37%) in the control group (p=0.02). The 
24-hour fluid balance was 2.1± 3.2 L in the treatment group compared to 1.9± 2.7 l in the 
control group (NS). Similarly, the 72- hour fluid balance was 1.9±3.7 L in the treatment 
group compared to 1.6 ± 3.3 L in the control group.  Vasopressors were weaned off all 
patients in the treatment group, a mean of 18.3 ± 9.8 hours after starting treatment with 
vitamin C protocol.  The dose of pressors was predictably weaned down between 2-4 hours 
after the first infusion of vitamin C. The mean duration of vasopressor use was 54.9 ± 28.4 
hours in the control group (p<0.001); 9 patients in the control group had escalating doses 
of vasopressors and died from refractory septic shock. The mean duration of vasopressors 
was 61.4 ± 33.8 hours in the control patient who died compared to 38.7± 6.5 hours in those 
who survived. The time course of the vasopressor dose (in norepinephrine  
equivalents) 36;37 in the treatment group, the control patients who died and the control 
patients who survived is illustrated in Figure 2.  The 72-hour delta SOFA score was 4.8 ± 
2.4 in the treatment group compared to 0.9 ± 2.7 in the control group (p<0.001). None of 
the patients in the treatment group developed progressive organ failure (an increase in 
their SOFA score) requiring an escalation of therapy. The time course of the SOFA score in 
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shown in Figure 3. The median 72 hours PCT clearance was 86.4 % (80.1-90.8) in the 
treatment group compared to 33.9% (-62.4 – 64.3) in the control group (p<0.001); the time 
course of the PCT over the first 4 days is illustrated in Figure 4. The median ICU LOS was 4 
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Discussion: 
   
  In this observational study the combination of intravenous vitamin C, moderate-
dose hydrocortisone and thiamine appeared to have a marked effect on the natural history 
of patients with severe sepsis and septic shock. No patient in the treatment group 
developed progressive organ failure and the four deaths in this group were related to the 
patients underlying disease; these patients did not die from sepsis related complications.  
Our study evaluated the use of intravenous vitamin C, hydrocortisone and thiamine in a 
real world setting where all eligible patients with sepsis were studied. This is important as 
less than 20% of eligible patient with severe sepsis and septic shock are commonly 
included in many of the sepsis trials limiting the applicability and generalizability of the 
results.61 Furthermore, we did not test an expensive, proprietary designer molecule, but 
rather the combination of three cheap and readily available agents with a long safety 
record in clinical use since 1949. 62;63  
 
   The findings of our study are supported by extensive experimental and clinical 
studies which have demonstrated the safety and potential benefit of  moderate-dose 
hydrocortisone, intravenous vitamin C and thiamine in critically ill patients. 16;17;21;26;64  
However, ours is the first study to evaluate the combination of  intravenous vitamin C 
hydrocortisone and thiamine, a combination which we believe synergistically reverses the 
pathophysiologic changes of sepsis.  The outcome data are supported by the time course of 
the PCT levels and SOFA score as well as the rapid decline in vasopressor requirements in 
the treatment group as compared to the control group. The time course of PCT in patients 
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studies have demonstrated a linear fall in PCT reaching about 30% of the baseline value in 
72 hours; a fall of greater than 30% over this time has been shown to indicate the 
appropriate use of antibiotics and is predictive of survival.  In the treatment group, the PCT 
fell exponentially in all patients reaching a median of 86% of the baseline value at 72 hours. 
In comparison, the PCT remained relatively unchanged in the control group during this 
time.  This observation is supported by the pilot study of Fowler et al who in a randomized 
controlled trial evaluated the clinical response to low dose (50 mg/kg/day) and high dose 
vitamin C (200 mg/kg/day) (without corticosteroids) in 24 patients with sepsis. 16 In this 
study, the fall of the PCT in the first 72 hours was approximately 40% in the low dose 
group and 80% in the high dose group whereas it increased in the control patients.  In our 
study, the mean time to vasopressor independence after starting the vitamin C protocol  
was 18 hours.  The mean duration of vasopressor therapy was 54 hours in the control 
group. The mean duration of vasopressor dependency in patients with septic shock 
reported in the literature varies between about 72 to 120 hrs. 37;54 In the VANISH trial, the 
median time to shock reversal was 45 hours (IQR 23-75hrs). 66 The mean duration of 
vasopressor dependency in the patients treated with vitamin C in the study by Fowler et al 
was 86 hrs.16 Similarly, in the Corticosteroid Therapy of Septic Shock (CORTICUS) study, 
the time to vasopressor independence was 79 hrs.  54 These data support the contention 
that vitamin C, hydrocortisone and thiamine have synergistic effects in reversing 
vasoplegic shock in patients with sepsis.  Shortening the duration of vasopressor treatment 
and preventing dose escalation likely has numerous beneficial effects, including limiting 
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bacterial growth-promoting effects, which may potentiate the immuno-paresis of sepsis 
thereby increasing the susceptibility towards secondary infections.69 
 
 Experimental studies performed over the last 20 years have demonstrated that both 
vitamin C and hydrocortisone have multiple and overlapping beneficial pathophysiologic 
effects in sepsis.  Vitamin C is a potent antioxidant which directly scavenges oxygen free 
radicals, restores other cellular antioxidants including tetrahydrobiopterin and α-
tocopherol and is an essential co-factor for iron and copper containing enzymes. 70;71 Both 
drugs inhibit nuclear factor Ƙ-B (NF-ƘB) activation down regulating the production of pro-
inflammatory mediators, increase tight junctions between endothelial and epithelial cells, 
preserve endothelial function and microcirculatory flow, and are required for the synthesis 
of catecholamines and increase vasopressor sensitivity.13-15;26;70-75 Vitamin C plays a major 
role in preserving endothelial function and microcirculatory flow.70;72 In addition, vitamin C 
activates the nuclear factor erythroid 2-like 2 (Nrf2)/ heme oxygenase (HO)-1 pathway 
which plays a critical role in anti-oxidant defences and enhances T cell and macrophage 
function. 76-78  The explanation as to why the combination of intravenous vitamin C, 
hydrocortisone and thiamine appeared to have a marked  effect on the course of sepsis as 
compared to the myriad of designer molecules which have been evaluated in previous 
sepsis trials is likely related to the multiple and overlapping effects of all three agents as 
compared to drugs which target a single molecule or pathway.12  Furthermore, we believe 
that vitamin C and corticosteroids act synergistically. 79 Oxidation of cysteine thiol groups 
of the glucocorticoid receptor (GR) affects ligand and DNA binding reducing the efficacy of 
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restore glucocorticoid function. 82 The transport of vitamin C into the cell is mediated by 
the sodium-vitamin C transporter -2 (SVCT2). 83 Proinflammatory cytokines have been 
demonstrated to decrease expression of SVCT2. 84 Glucocorticoids, however, have been 
shown to increase expression of SVCT2. 85 In an experimental model using cultured human 
lung vascular endothelial cells exposed to endotoxin we have demonstrated that incubation 
with the combination of vitamin C and hydrocortisone preserved endothelial integrity  as 
compared to either agent alone which was no more effective than placebo.86  This finding is 
in keeping with recent clinical studies which suggest that hydrocortisone and vitamin C 
alone have little impact on the clinical outcome of patients with sepsis.16;54  The recently 
published “Hydrocortisone for Prevention of Septic Shock (HYPRESS)” study failed to 
demonstrate an outcome benefit from a hydrocortisone infusion in patients with severe 
sepsis.87  
 
 While the dosing strategy for corticosteroids (hydrocortisone) in patients with 
severe sepsis and septic shock has been well studied,26;88 that for vitamin C is more 
uncertain. Critically ill patients have either very low or undetectable vitamin C levels 
(normal serum levels 40-60 umol/l).18;19 Due to the saturable intestinal transporter 
(sodium-vitamin C transporter-1), 20;83 oral administration of doses as high as 1500 mg 
cannot restore normal serum levels. 20 To achieve normal serum vitamin C levels in 
critically ill patients, a daily dose of more than 3 gm is required. 16;18;21 Based on 
pharmacokinetic data and preliminary dose response data we believe that a daily dose of  
6gm combined with hydrocortisone is optimal.  When high dosages of vitamin C are given 
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the kidney and serum levels will increase with renal impairment. In patients with renal 
impairment receiving mega-dose vitamin C, supersaturation of serum with oxalate may 
result in tissue deposition as well as crystallization in the kidney. 89;90 Worsening renal 
function is therefore a concern with mega-dose vitamin C.  It is noteworthy that renal 
function improved in all our patients with AKI.  Glyoxylate, a byproduct of intermediary 
metabolism, is either reduced to oxalate or oxidized to CO2 by the enzyme glyoxylate 
aminotransferase; thiamine pyrophosphate is a co-enzyme required for this reaction. 91 
Thiamine deficiency increases the conversion of glyoxylate to oxalate. 92;93 Thiamine 
deficiency is common in septic patients and associated with an increased risk of death.64 
For these reasons, thiamine was included in our vitamin C protocol.    
 
  
Our study has several limitations, namely the small sample size, single center 
design, and the use of non-concurrent controls.  Furthermore, the treatment and control 
periods occurred during different seasons.  We used propensity score adjustment in an 
attempt to control for some of these factors.  We believe that the data from our study is 
internally consistent, has valid mechanistic basis and is supported by experimental studies.  
In addition, the safety of hydrocortisone, vitamin C and thiamine is supported by over 50 
years of clinical experience.   Due to the inherent safety of the combination of 
hydrocortisone, vitamin C and thiamine we believe that this treatment strategy can be 
adopted pending the results of further clinical trials. We believe that the results of our 
study provide sufficient information for the design of an adequately powered, high quality 
pragmatic trial to confirm the findings of our study.  Due to the lack of clinical equipoise 
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initiate a RCT in our center.   Furthermore, while our observational study suggests that a 4-
day course of vitamin C is optimal additional studies are required to determine the ideal 
dosing strategy and the contributing role of thiamine requires further exploration.  
 
In conclusion, the results of our study suggest that the early use of intravenous 
vitamin C, together with moderate-dose hydrocortisone and thiamine may prove to be 
effective in preventing progressive organ dysfunction including acute kidney injury and 
reducing the mortality of patients with severe sepsis and septic shock.  This inexpensive 
and readily available intervention has the potential to reduce the global mortality from 
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Table 1.  Baseline characteristic of treated and control patients. 
 
    Treated (n=47)  Control (n=47) ‡ 
Age     58.3 ± 14.1   62.2 ± 14.3 
Sex (male)    27 (57%)   23 (49%) 
Comorbidities 
 None     2 (4%)   1 (2%) 
Diabetes   16 (34%)   20 (42%) 
 Hypertension   20 (43%)   25 (53%) 
 Heart Failure   15 (32%)   16 (34%) 
 Malignancy   5 (11%)   7 (15%) 
 COPD    8 (17%)   7 (15%) 
Cirrhosis   6 (13%)   3(6%) 
CVA    8 (17%)   5 (11%) 
CRF    7 (15%)   8 (17%) 
Morbid Obesity  6 (13%)   8 (17%) 
Immunocompromised** 6 (13%)   4 (9%) 
Drug addiction  5 (11%)   5 (11%) 
Primary diagnosis 
 Pneumonia   18 (38%)   19 (40%) 
 Urosepsis   11(23%)   10 (21%) 
 Primary bacteremia  7 (15%)   7 (15%) 
 GI/ Biliary   6 (13)    6 (13%) 
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Mechanical Ventilation 22 (47%)   26 (55%) 
Vasopressors   22 (46%)   22 (46%) 
Acute kidney injury  31 (66%)   30 (64%)  
Positive Blood cultures 13 (28%)   13 (28%) 
WBC x109†   20.6 ± 13.5   17.1 ± 13.4 
Lactate (mmol/l)  2.7 ± 1.5   3.1 ± 2.8 
Creatinine (mg/dl)††  1.9 ± 1.4   1.9 ± 1.1 
Procalcitonin (ng/ml) 25.8 (5.8- 93.4)  15.2 (5.9 -39.0) 
Day 1 SOFA   8.3 ± 2.8   8.7 ± 3.7 
APACHE II   22.1 ± 6.3   22.6 ± 5.7 
APACHE IV   79.5 ± 16.4   82.0 ± 27.4 
Predicted mortality  39.7 ± 16.7   41.6 ± 24.2 
 
‡ No significant difference in baseline characteristics between groups 
* CVA=cerebrovascular accident; COPD=chronic obstructive lung disease; CRF =chronic 
respiratory failure; GI=gastrointestinal 
** HIV infection, neutropenia, post-transplant, etc.  
† Excluding neutropenic patients  
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Table 2. Outcome and treatment variables  
 
     Treated (n=47)  Control (n=47)  
 
Hospital mortality   4 (8.5%)   19 (40.4%)† 
 
ICU LOS    4 (3-5)   4 (4-10) 
 
Duration of vasopressors (hours) 18.3 ± 9.8   54.9 ± 28.4 † 
 
RRT for AKI    3/31 (10%)   11/30 (33%)†† 
 
Delta SOFA (72 hr)   4.8 ± 2.4   0.9 ± 2.7 † 
 
Procalcitonin Clearance (72 hr) 86.4% (80.1-90.8)  33.9% (-62.4 – 64.3) † 
 
 
RRT= renal replacement therapy; AKI= acute kidney injury 
 
† p < 0.001 
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Legends for Figures. 
 
Figure 1. Predicted and actual mortality in the treatment and control group. Predicted 
mortality was derived from the APACHE IV scoring system. p< 0.001 for comparison of 
treatment vs control group (see text) 
 
 
Figure 2.   
Time course of vasopressor dosage (in norepinephrine equivalents) in the treatment group 
and in the control group survivors and non-survivors. p< 0.001 for comparison of 
treatment vs control group (see text) 
 
 
Figure 3.  
Time course of the SOFA score over the four-day treatment period in the treatment group 
and in the control group survivors and non-survivors. p< 0.001 for comparison of 




Time course of the PCT score over the four-day treatment period in the treatment group 
and in the control group survivors and non-survivors plotted on a semilog scale. p< 0.001 
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